FDA Places Clinical Hold on Kezar Life Sciences Zetomipzomib IND for Lupus Nephritis South San Francisco-based biotechnology firm, Kezar Life Sciences, Inc. (Nasdaq: KZR), announced a significant regulatory development regarding its promising therapeutic candidate, zetomipzomib. The U.S. Food and Drug Administration (FDA) has decided to impose a clinical hold on the Investigational New Drug (IND) application for zetomipzomib, a novel small molecule developed for the treatment of lupus nephritis (LN). This clinical hold was communicated through a teleconference between Kezar officials and the FDA.As lupus nephritis remains a significant unmet medical need within the spectrum of immune-mediated diseases, zeto...
In the ever-evolving landscape of clinical trials, some moments shine bright with promise, while others echo with caution. Kezar Life Sciences, a prominent player in the biotechnology arena, recently announced a pivotal juncture in the development of its lead candidate, Zetomipzomib, targeting active lupus nephritis (LN). The company’s decision to voluntarily cease enrollment and dosing of new and ongoing patients in the Phase 2b PALIZADE trial reflects a thoughtful strategy amidst a complex interplay of clinical data and patient safety considerations.Lupus nephritis, an often debilitating complication of systemic lupus erythematosus (SLE), presents a significant challenge for healthcare providers and pati...
Kezar Life Sciences Reports Positive Financial Results and Promising Advances in Immune-Mediated Disease and Cancer TherapiesSOUTH SAN FRANCISCO, Calif. - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company specializing in the development of innovative small molecule therapeutics for immune-mediated diseases and cancer, has announced its financial results for the first quarter ended March 31, 2024. The company also provided updates on its latest breakthroughs and advancements in the field.Over the past quarter, Kezar Life Sciences has witnessed significant strides in its mission to develop pioneering small molecule therapeutics in immunology and oncology. The company s dedication ...
Sources:
Kezar Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kezar Life Sciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kezar Life Sciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
